K 012610 Pg 182



510(k) Summary of Safety and Effectiveness Phomix, Arizono 85044

Alliance Medical Corporation

10232 South 51st Street Phoenix, Arizona 85044 TEL 480.763.5300 FAX 480.763.5310 Toli Free 888.888.3433 www.alliance-medical.com

Contact:

Submitter:

Don Selvey

Vice President, Regulatory Affairs and Quality Assurance

(480) 763-5300

Date of preparation:

August 5, 2001

Name of device:

Alliance Medical Corporation Reprocessed Polypectomy Snares

C.R. Bard, Inc.	Optimizer TM Polypectomy Snare	00472, 00473, 000475, 00477, 00479
Boston Scientific	Microvasive® OneSpare	6206, 6208
Boston Scientific	Microvasive® Captivator Polypectomy Snare	6131, 6230
Boston Scientific	Microvasive® Captiflex TM Polypectomy Snare	6240, 6242
Boston Scientific	Microvasive® Sensation TM Polypectomy Spare	6265, 6267, 6269
Olympus America, Inc	Disposable Electorsurgical Snare	SD-210U-10, SD-210U-15, SD-210U-25
Wilson Cook® Medical, Inc.	AcuSnare® Polypectomy	ASM-1, SAS-1, SASJ-1, SASM-1

K#	Device Description	Procode
K950496	Boston Scientific Microvasive Single-Use Polypeciomy Snare	FDI
K941750	Boston Scientific Microvasive® Polypectomy Snare	FDI
K955650	Olympus SD Series Snares	FDI
K923031	Cook Urelegical Endosnare	FDI
K955650	Ohympus SD Series Snares	FOI
K902735	Ohympus SD Snares	GEI
K945016	Bard Davel Polypectomy Snare	KOG

K012610.

Device description:

Polypectomy snares are specially designed endoscopic instruments composed of a handle and a wire cable with a loop for use in the endoscopic excision of gastrointestinal polyps. An active cord connects the monopolar polypectomy snare to a variety of monopolar generators. When activated, the loop of the snare will cut and cauterize tissue using monopolar electrical current.

Intended use:

Reprocessed polypectomy snares are intended to be used endoscopically to remove and cauterize polyps and other tissue in the gastrointestinal tract.

Indications statement:

Reprocessed polypectomy snares are indicated for use in patients requiring removal and cauterization of polyps in the gastrointestinal tract.

Technological characteristics:

The intended use and technological features of the reprocessed devices do not differ from the legally marketed predicate device(s). Both the submitted device(s) and the predicate device(s) have the same materials and product design. The technological characteristics of the submitted reprocessed polypectomy snares are the same as those of the legally marketed predicate devices.

Alliance Medical Corporation reprocessing of polypectomy snares includes removal of adherent visible soil and decontamination and thorough rinsing of all cleaning agents. Complete removal of residual moisture is accomplished using forced-air drying. Each individual instrument is tested for electrical continuity and appropriate extension of the snare loop prior to packaging, labeling, and sterilization operations.

Performance data:

Performance data demonstrates that Reprocessed Polypectomy Snares perform as originally intended.

Conclusion:

In accordance with the Federal Food, Drug and Cosmetic Act, 21 CFR Part 807 and based on the information provided in this premarket notification, Alliance Medical Corporation concludes that the modified device (Reprocessed Polypectomy Snares) is safe, effective, and substantially equivalent to the predicate devices as described herein.



Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

FEB 1 9 2002

Mr. Don Selvey Vice President Regulatory Affairs and Quality Assurance Alliance Medical Corporation 10232 South 51st Street PHOENIX AZ 85044

Re: K012610

Trade/Device Name: Alliance Preprocessed

Polypectomy Snares

(see attached list)

Regulation Number: 21 CFR § 876.4300

Regulation Name: Endoscopic electrosurgical

Unit and accessories

Regulation Class: II Product Code: 78 FDI Dated: November 14, 2001

Received: November 28, 2001

Dear Mr. Selvey:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at one of the following numbers, based on the regulation number at the top of this letter:

$-0_{\text{erg}} + 1_{\text{VVV}}$ (301) 3:	94-4591
8xx.1xxx 876.2xxx, 3xxx, 4xxx, 5xxx (301) 55	94-4616
884.2xxx, 3xxx, 4xxx, 5xxx, 6xxx (301) 55	94-4616
892.2xxx, 3xxx, 4xxx, 5xxx (301) 55	94-4654
Other (301) 59	94-4692

Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html.

Sincerely yours,

Mancy Chrogdon
Nancy C. Brogdon

Director, Division of Reproductive, Abdominal, and Radiological Devices

Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

Indications for Use Statement

510(k) Nember (illinown):

Device Name: Alliance Medical Corporation Reprecessed Polypectomy Snares

Indications for Use: Reprocessed polypectomy snages are indicated for use in patients requiring removal and camerization of polyps in the gastrointestical tract.

PARTIES AND A STREET AND A STRE		00472,400473.
	:	000475, 00477,
CR. Band, Inc.	Optimizer TM Polypectomy Snare	00479
Boston Scientific	Microvasive® OneSpare	
	Polypectomy Snare	6206, 6208
Baston Scientific	Microvasive® Captivator	
	Perspectomy Share	6131, 6230
Besten Scientific	Microvasive® Captiflex TM]
	Pelypectomy Spane	6240, 6342
Boston Scientific	Microvasive® Sensation To	•
	Polypectoniny Sume	<i>1</i> 6265, 6267, 6269
	1	SD-210U-10,
Olympus America Inc	Disposable Electorsurgical Snare	SD-210U-15,
		SD-210U-25
		ASM-1, SAS-1,
Wilson Cook®	AcuSnare® Polypectomy Snare	SASJ-1, SASM-1
Medical, Inc.		

Concernance of CDRH, C	Mice of Device Evaluation (ODE)	
Prescription Use	Mancy C Svogdon	
	(Division Sign-Off) Division of Reproductive, Abdominal, and Radiological Devices 510(k) Number	

CONFIDENMAL